Discovery and Innovation

Aeglea

[ey-glee-uh]

From the Latin name Aegle.
The goddess of radiant good
health. Daughter of Asclepius,
the god of medicine.

As a leader in creating and developing novel engineered human enzymes to degrade specific amino acids in the blood, we are focused on providing safe and effective products to patients.

What does success mean to us? It means…

  • Unlocking the potential therapeutic value of engineered human enzymes while avoiding immune responses
  • Meeting serious unmet medical needs in rare genetic diseases, inborn errors of metabolism, and cancers with ground-breaking treatments
  • Transforming lives, especially those of children and families

Built on discovery, technology, and opportunity, our biotechnology company was founded in 2013 to develop and bring to market the engineered human enzymes invented in the lab of Professor George Georgiou, Ph.D., University of Texas at Austin.

Our numbers tell part of our unique story:

100%

Percentage of Aeglea employees personally affected by a family member with cancer and/or rare disease

1

Included in Austin Business Journal’s “Austin’s Best Places to Work” 2016

23

Months from company’s inception to first patient dosed in a clinical study

1,323

Miles ridden by bicycle by one employee for disease awareness

38

Drug, device, and diagnostic approval experience of Aeglea employees

Read on to meet our management and scientific team – these are the inspiring individuals at the forefront of modulating extremes of amino acid metabolism.

Leadership Team

David G. Lowe, Ph.D.

President and Chief Executive Officer

Anthony Quinn, M.B Ch.B, Ph.D.

Interim Chief Medical Officer

Charles N. York II, M.B.A.

Chief Financial Officer

Stephen Eckert, Ph.D.

Vice President of Biometrics

Henry L. Hebel, M.B.A.

Vice President of Operations

Scott W. Rowlinson, Ph.D.

Vice President of Research

Joseph E. Tyler, M.S.

Vice President of Manufacturing

Board of Directors

David G. Lowe, Ph.D.

President and Chief Executive Officer

Russell J. Cox

Executive Vice President and Chief Operating Officer, Jazz Pharmaceuticals

George Georgiou, Ph.D.

Laura Jennings Turner Endowed Chair Professor, Departments of Chemical Engineering and Molecular Biosciences, University of Texas at Austin

Sandy Mahatme

Executive Vice President, Chief Financial Officer, and Chief Business Officer, Sarepta Therapeutics, Inc.

Anthony Quinn, M.B Ch.B, Ph.D.

Interim Chief Medical Officer

Armen Shanafelt, Ph.D.

General Partner, Lilly Ventures

Suzanne L. Bruhn, Ph.D.

Suzanne L. Bruhn, Ph.D.

President and Chief Executive Officer, Proclara Biosciences, Inc.

Scientific Advisors

Keith Flaherty, M.D.

Dr. Flaherty is the director of the Henri and Belinda Termeer Center for Targeted Therapies at the Massachusetts General Hospital Cancer Center and a professor of medicine at Harvard Medical School. Previously, he was an assistant professor of medicine at the University Of Pennsylvania School of Medicine and an adjunct professor at The Wistar Institute. His research and clinical focus is on therapies for melanoma, with a particular expertise in targeted therapies. Dr. Flaherty has been the principal investigator of many clinical trials, including first-in-human trials of novel target therapies. He serves as a senior editor for Clinical Cancer Research and is a member of the editorial boards for Cancer Discovery, Journal of Clinical Oncology, Cancer and Pigment Cell and Melanoma Biology. Dr. Flaherty earned his M.D. from Johns Hopkins University and completed his residency in medicine at Brigham and Women’s Hospital at Harvard Medical School.

Arthur Frankel, M.D.

Dr. Frankel is a professor of internal medicine in the division of Hematology and Oncology at UT Southwestern Medical Center and leader of Phase 1 clinical trials at the Harold Simmons Comprehensive Cancer Center. Previously, he served as professor of medicine and head of the Division of Hematology and Oncology at the Scott & White Hospital and Texas A&M School of Medicine, where he was also executive director of the Cancer Research Institute. Dr. Frankel earned his M.D. from Harvard Medical School and completed his residency in medicine and a fellowship in oncology at Stanford University. He is board-certified in internal medicine, medical oncology and hematology.

Wayne Klohs, Ph.D.

Dr. Klohs served as senior vice president and global therapeutic head of Oncology at Astellas Pharma until his retirement in 2013. At Astellas, Dr. Klohs helped build the company’s global oncology business with several marketed products including Tarceva® and Xtandi®. He has previously served as head of Oncology Clinical Sciences at Takeda Global R&D, where he led early and late-stage development teams in oncology, and executive director of oncology drug development at Pfizer, Inc.

Matthew Vander Heiden, M.D., Ph.D.

Dr. Vander Heiden is the Eisen and Chang Associate Professor in the Koch Institute for Integrative Cancer Research and the Department of Biology at the Massachusetts Institute of Technology. He is also an Institute Member of the Broad Institute of Harvard and MIT, and an Instructor in Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. His laboratory studies how metabolism is regulated to meet the needs of cells in different physiological situations, with a major focus of his research on the role of metabolism in cancer. Dr. Vander Heiden earned his M.D. and Ph.D. degrees from the University of Chicago. He also completed clinical training in internal medicine and medical oncology at the Brigham and Women’s Hospital / Dana-Farber Cancer Institute prior to completing a post-doctoral fellowship at Harvard Medical School.

Daniel D. Von Hoff, M.D.

Dr. Von Hoff is physician-in-chief and distinguished professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He is also chief scientific officer for HonorHealth Clinical Research Institute, medical director of research at McKesson Specialty Health, U.S. Oncology Research and a professor of medicine at The Mayo Clinic in Scottsdale, Arizona. He served a six-year appointment on President George W. Bush’s National Cancer Advisory Board and has served on the FDA’s Oncology Advisory Committee. Dr. Von Hoff is also the past president of the American Associate for Cancer Research (AACR), and was a member of the American Society of Clinical Oncology’s (ASCO) Board of Directors. He received the 2010 David A. Karnofsky Memorial Award from ASCO for his outstanding contributions to cancer research leading to significant improvement in patient care. He earned his M.D. from Columbia University and completed his residency in internal medicine at the University of California, San Francisco. He is a fellow of the American College of Physicians.

Contact Us

Aeglea BioTherapeutics

CORPORATE HEADQUARTERS
901 S. MoPac Expressway, Barton Oaks Plaza One,
Suite 250, Austin, TX 78746

MAILING ADDRESS
901 S. MoPac Expressway, Barton Oaks Plaza One,
Suite 250, Austin, TX 78746

TELEPHONE NUMBER
(512) 942-2935

FAX NUMBER
(512) 872-5121

INVESTOR INQURIES
investors@aegleabio.com

MEDIA INQUIRIES
media@aegleabio.com

Send Us a Message
  • This field is for validation purposes and should be left unchanged.

David G. Lowe, Ph.D.

President and Chief Executive Officer

Dr. Lowe is the co-founder, president and chief executive officer of Aeglea BioTherapeutics and its affiliates. Before leading the formation of Aeglea, he was a venture capitalist at Skyline Ventures, Palo Alto, California, where he led financings in start-ups to mid-stage healthcare companies. Dr. Lowe began his career as a molecular biologist, joining Genentech as a postdoctoral fellow, and ultimately becoming a research director. At Genentech he was responsible for drug discovery activities in biologics and small molecule therapeutics, efforts that resulted in eight drugs that moved into clinical development, including two eventual products. Dr. Lowe also serves on the board of Shattuck Labs.

F. Andrew Dorr, M.D.

Interim Chief Medical Officer

Dr. Dorr oversees the medical strategy and clinical development of Aeglea’s pipeline. An oncologist by training, Dr. Dorr has extensive experience leading drug development for the treatment of rare cancers, including Treanda® (bendamustine) for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. He has served as an independent consultant for cancer drug development since 2005, including advising on strategic and therapeutic development opportunities for rare diseases like Duchenne’s Muscular Dystrophy, pigmented villonodular synovitis, thrombotic microangiopathy and BRCA mutation-associated cancers. Previously, Dr. Dorr was chief operating officer at Salmedix, Inc. Prior to Salmedix, Dr. Dorr was at Ionis (previously known as Isis) Pharmaceuticals, Inc., initially serving as vice president of oncology drug development and eventually taking the role of chief medical officer. He has also served as a clinical research physician and medical advisor at Eli Lilly and Company, where he was responsible for cancer pipeline strategy from pre-clinical through Phase 3 development.

Charles N. York II, M.B.A.

Chief Financial Officer

Prior to joining Aeglea, Mr. York held CFO and other finance leadership positions in public companies and high-growth start-ups in the technology, aerospace, medical devices, and pharmaceutical industries. Mr. York’s transactional background includes various corporate finance roles in a private equity M&A deal, a corporate spin-off and an IPO. Operationally, Mr. York was instrumental in planning and executing a strategic realignment and capital restructuring of a publicly traded company, which contributed to a positive financial return to equity holders during his tenure. Mr. York is a Certified Public Accountant (CPA) who earned his B.S. in accounting from the University of Connecticut and his M.B.A. from the McCombs School of Business at the University of Texas at Austin.

Henry L. Hebel, M.B.A.

Vice President of Operations

Prior to joining Aeglea, Mr. Hebel served as the vice president of drug development for Terapio, where he successfully developed a radiation countermeasure product allowing entry into critical government countermeasure development programs. Additionally, Mr. Hebel was chief operating officer of VGXI Inc., where he led the virtual company to operational in-house cGMP production in support of FDA and USDA clinical submissions within two years. VGXI continued to expand operations under Mr. Hebel’s guidance and successfully obtained the world’s first commercial gene therapy medical device combination product approval. Prior to VGXI, Mr. Hebel served as key account manager at Qiagen, Inc. for the strategic joint venture known as the “pAlliance.” Mr. Hebel also worked as the senior manager of bioprocessing for GeneMedicine Inc., and has additional antibody product development and manufacturing experience at Tanox Biosystems, Inc. Mr. Hebel holds a B.S. in Zoology and an M.B.A from Texas A&M University.

Scott W. Rowlinson, Ph.D.

Vice President of Research

Dr. Rowlinson joins Aeglea from Eli Lilly and Company. He has a proven track record of scientific productivity in biologics drug discovery and development, and has demonstrated leadership in coordinating drug discovery to clinical development. These efforts led to three successful IND submissions, the most advanced being in Phase 2 development. Dr. Rowlinson has a wealth of experience in the broader concepts of biomolecule drug development, including uncovering factors involved in clinical portfolio attrition and optimal integration of companion diagnostic development and drug development. He holds a Ph.D. in physiology and biochemistry from University of Queensland in Brisbane, Australia.

Joseph E. Tyler, M.S.

Vice President of Manufacturing

Mr. Tyler has worked for over 40 years in the pharmaceutical and biotechnology field in process development, manufacturing, and CMC program management. Mr. Tyler has worked for Schering Corp, Lederle Laboratories, Abbott Laboratories, Stryker Biotech, GelTex Pharmaceuticals, Salix Pharmaceuticals, Momenta Pharmaceuticals, KBI Biopharma, and Proteon Therapeutics. He has managed CMC development programs, ultimately gaining approval in the U.S. and Europe for five new medications, including sevelamer, cosevelem, rifaximin, a new antibiotic indicated for C. difficile infections and a novel lipid management drug. Mr. Tyler recently was the CMC program leader for a recombinant human enzyme that will be starting Phase 3 clinical trials this year. He received a B.S. in chemical engineering from Carnegie Mellon University and an M.S. in biochemical engineering from Cornell University.

Stephen Eckert, Ph.D.

Vice President of Biometrics

Prior to joining Aeglea, Dr. Eckert served as Vice President, Global Clinical Affairs for Acelity. He has over 20 years of experience in biostatistical design and analysis for pharmaceutical, biologic, and medical device clinical trials, including several successful regulatory submissions across multiple therapeutic areas. In addition to experience with medical device studies for wound healing with Acelity, he has experience with endocrine system clinical studies with Eli Lilly & Company; cardiovascular, metabolic, and solid tumor clinical studies with Pfizer; leukemia clinical studies with Genzyme; and studies of inborn errors of metabolism with Synageva Biopharma. He has also held team leader roles providing strategic product development direction for teams comprised of physicians, regulatory scientists, and other drug development experts. Dr. Eckert holds a B.S. in Applied Mathematics, as well as M.S. and Ph.D. degrees in Statistics, from Texas A&M University.

Russell J. Cox

Executive Vice President and Chief Operating Officer, Jazz Pharmaceuticals

Mr. Cox is executive vice president and chief operating officer of Jazz Pharmaceuticals. He has served in a variety of escalating senior management roles since joining the company in 2010, including executive vice president and chief commercial officer from March 2012 to May 2014. From January 2009 to January 2010, he was senior vice president and chief commercial officer of Ipsen Group, and from 2007 until December 2008 he was vice president of marketing at Tercica, Inc. (acquired by Ipsen Group), a biotechnology company. From 2003 to 2007, he was with Scios, Inc. (acquired by Johnson & Johnson in 2003), where he also held the role of vice president of marketing. Prior to 2003, Mr. Cox was with Genentech, Inc. for 12 years, where he was a product team leader responsible for the growth hormone franchise and led numerous product launches as a group product manager. Mr. Cox received a B.S. in biomedical science from Texas A&M University.

George Georgiou, Ph.D.

Laura Jennings Turner Endowed Chair Professor, Departments of Chemical Engineering and Molecular Biosciences, University of Texas at Austin

Professor Georgiou holds the Laura Jennings Turner Chair in Engineering at the University of Texas at Austin, where he serves on the faculties of chemical engineering, biomedical engineering, and molecular biosciences. A prolific inventor, Dr. Georgiou holds 37 issued and 52 pending U.S. patents. More than 70 percent of these, comprising 16 distinct technology suites, have been licensed to 18 pharmaceutical or biotechnology companies. Before co-founding Aeglea, he founded GGMJ, acquired by Maxygen (NASDQ: MAXY) in 2000. Dr. Georgiou was elected member of the National Academy of Engineering in 2005, the National Academy of Medicine in 2011, as well as the American Academy of Arts and Sciences and the National Academy of Inventors in 2015. He was named one of “Top 20 Translational Researchers” by Nature Biotechnology in 2015 and one of “100 Eminent Chemical Engineers of the Modern Era” by the American Institute of Chemical Engineering (AIChE) in 2008. He received his B.S. in chemical engineering from the University of Manchester, UK and his M.S. and Ph.D. from Cornell.

Sandy Mahatme

Executive Vice President, Chief Financial Officer, and Chief Business Officer, Sarepta Therapeutics, Inc.

Mr. Mahatme is senior vice president and chief financial officer of Sarepta Therapeutics. From January 2006 to November 2012, Mr. Mahatme worked at Celgene Corporation, a biopharmaceutical company, where he served in various roles, including senior vice president of corporate development, senior vice president of finance, corporate treasurer, and head of tax. While at Celgene, Mr. Mahatme built the treasury and tax functions before establishing the corporate development department, focused on strategic, targeted initiatives including commercial development in emerging markets, acquisitions and licensing, and global manufacturing expansion. Prior to working at Celgene, Mr. Mahatme worked for Pfizer Inc. for eight and a half years in senior roles in business development and corporate tax. Mr. Mahatme started his career at Ernst & Young LLP, where he advised multinational corporations on a broad range of transactions. Mr. Mahatme holds Master of Law degrees from Cornell Law School and New York University School of Law and is a member of the New York State Bar Association. In addition to Aeglea, Mr. Mahatme is also a board member of Flexion Therapeutics, Inc. and Elcelyx Therapeutics, Inc., both biopharmaceutical companies.

Anthony Quinn, M.B Ch.B, Ph.D.

Interim Chief Medical Officer

Dr. Quinn most recently served as executive vice president, head of research and development, and chief medical officer at Synageva Biopharma Corp. until the company’s acquisition by Alexion Pharmaceuticals in 2015. During his tenure at Synageva, he played a key role in securing the European and U.S. approvals of Kanuma™ for Lysosomal Acid Lipase Deficiency and in building the company’s research and development organization and rare disease drug pipeline. Prior to his role at Synageva, Dr. Quinn served as worldwide head of clinical research and exploratory development for inflammatory diseases at Roche. Previously, he was a professor of dermatology at Barts and The London School of Medicine. He received his Bachelor of Medical Science and his M.B Ch.B from the University of Dundee, and a Ph.D. from the University of Newcastle upon Tyne. Dr. Quinn completed a postdoctoral fellowship at the University of California San Francisco and is a fellow of the Royal College of Physicians London.

Armen Shanafelt, Ph.D.

General Partner, Lilly Ventures

Dr. Shanafelt is a general partner at Lilly Ventures. Prior to joining Lilly Ventures in 2009, he had over 24 years of experience in the pharmaceutical, biotechnology, and diagnostic industries. In addition to Aeglea, Dr. Shanafelt serves as a director on the boards of Aileron Therapeutics, Protagonist Therapeutics (PTGX), Sutro Biopharma, Surface Oncology and Symic Bio, where he serves as chairman. He also sits on the advisory board for the University of Texas System Horizon Fund and is a Kauffman Fellow (class of 2014). Dr. Shanafelt received his B.S. in chemistry and physics from Pacific Lutheran University and his Ph.D. in chemistry from the University of California, Berkeley. He completed his postdoctoral work at DNAX Research Institute.

Suzanne L. Bruhn, Ph.D.

Suzanne L. Bruhn, Ph.D.

President and Chief Executive Officer, Proclara Biosciences, Inc

Dr. Bruhn most recently served as president and chief executive officer of Promedior, Inc., a privately held, clinical-stage immunotherapy company developing targeted therapeutics to treat diseases involving fibrosis. She successfully negotiated an exclusive agreement for the right to acquire the company by Bristol-Myers Squibb in 2015.  Prior to that, Dr. Bruhn held a series of positions with increasing responsibility at Shire Human Genetic Therapies (HGT), a division of Shire plc, specializing in the development and commercialization of treatments for orphan diseases. During her tenure at Shire HGT, Dr. Bruhn was responsible for establishing the program management function, driving strategic planning and portfolio management and for global regulatory affairs. She played a key role in the development, registration and global expansion of Shire’s orphan product portfolio.  Prior to her time at Shire, Dr. Bruhn held various positions at Cytotherapeutics, Inc., a biotechnology company. Dr. Bruhn holds a Ph.D. in chemistry from Massachusetts Institute of Technology and was a postdoctoral fellow in the Department of Human Genetics at Harvard Medical School. In addition to Aeglea, Dr. Bruhn currently serves as a director on the board of Pliant Therapeutics, a biotechnology company.